


## CLAIM AMENDMENTS

1 - 5. (canceled)

6. (New) A pharmaceutical composition for the treatment  
of pain which consists essentially of:

(a) 70 to 95% w/w compound of formula I



I

wherein R is a methyl or ethyl group, as active ingredient and

(b) 5 to 30 % w/w of dextromethorphan, as a potentiator  
of the compound of the Formula (I), together with a  
pharmaceutically acceptable inert carrier.

7. (New) The pharmaceutical composition according to  
claim 6, wherein the compound of formula I, wherein R is a methyl  
group is present in an amount of 80 to 90% w/w and dextromethorphan  
is present in an amount of 10 to 20% w/w.

1                   8. (New) The pharmaceutical composition according to  
2 claim 6 wherein a unit of the composition contains 150 mg  
3 tolperisone and 30 mg dextromethorphan in admixture with a  
4 pharmaceutically acceptable inert carrier.

1                   9. (New) The pharmaceutical composition according to  
2 claim 8 wherein the unit of the composition includes a  
3 pharmaceutically acceptable inert carrier suitable for oral  
4 administration.

1                   10. (New) A method of treating and/or inhibiting pain  
2 which comprises the step of administering to a patient in need of  
3 said treatment, an analgesically effective amount of the  
4 pharmaceutical composition defined in claim 6.

1                   11. (New) The method of treating and/or inhibiting pain  
2 defined in claim 10 wherein the pharmaceutical composition is  
3 orally administered to the patient in need of said treatment.

1                   12. (New) A synergistic pharmaceutical composition for  
2 treating spasticity which consists essentially of as active  
3 ingredients:

4                   (a) 40 to 60 parts by weight of tolperisone or eperisone;  
5 and

6 (b) 10 parts by weight of dextromethorphan, together with  
7 a pharmaceutically acceptable inert carrier.

1 13. (New) The pharmaceutical composition according to  
2 claim 12 wherein the active ingredients are 40 to 60 parts by  
3 weight of tolperisone and 10 parts by weight of dextromethorphan.

1 14. (New) The pharmaceutical composition according to  
2 claim 13 wherein a unit of the composition contains 150 mg  
3 tolperisone and 30 mg dextromethorphan in admixture with a  
4 pharmaceutically acceptable inert carrier.

1 15. (New) The pharmaceutical composition according to  
2 claim 12 wherein the unit of the composition includes a  
3 pharmaceutically acceptable inert carrier suitable for oral  
4 administration.

1 16. (New) A method of treating and/or inhibiting  
2 spasticity which comprises the step of administering to a patient  
3 in need of said treatment, an anti-spasmodically effective amount  
4 of the synergistic pharmaceutical composition defined in claim 12.

1                   17. (New) The method of treating and/or inhibiting  
2   spasticity defined in claim 16 wherein the pharmaceutical  
3   composition is orally administered to the patient in need of said  
4   treatment.